American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 732-740 , October 2009

CKD in MYH9-Related Disorders

  • Neeraj Singh, MBBS

      Affiliations

    • Department of Internal Medicine, Section of Nephrology, The Ohio State University, Columbus, OH
    • Corresponding Author InformationAddress correspondence to Neeraj Singh, MBBS, The Ohio State University Medical Center, Division of Nephrology, Columbus, OH 43210
    • ,
  • Neha Nainani, MBBS

      Affiliations

    • Department of Internal Medicine, Section of Nephrology, The State University of New York at Buffalo, Buffalo, NY
    • ,
  • Pradeep Arora, MD

      Affiliations

    • Department of Internal Medicine, Section of Nephrology, The State University of New York at Buffalo, Buffalo, NY
    • ,
  • Rocco C. Venuto, MD

      Affiliations

    • Department of Internal Medicine, Section of Nephrology, The State University of New York at Buffalo, Buffalo, NY

Received 7 February 2009 ,Accepted 5 June 2009.

References 

  1. Seri M, Cusano R, Gangarossa S, et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes (The May-Hegglin/Fechtner Syndrome Consortium). Nat Genet. 2000;26:103–105
  2. Kelley MJ, Jawien W, Ortel TL, Korczak JF. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet. 2000;26:106–108
  3. Seri M, Savino M, Bordo D, et al. Epstein syndrome: Another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet. 2002;110:182–186
  4. Kunishima S, Kojima T, Tanaka T, et al. Mapping of a gene for May-Hegglin anomaly to chromosome 22q. Hum Genet. 1999;105:379–383
  5. May R. Leukozyteneinschlusse. Deutsch Arch Klin Med. 1909;96:1–6
  6. Hegglin R. Gleichzeitige konstitutionelle veranderungen an neutrophilen und Thrombozyten. Helv Med Acta. 1945;12:439–440
  7. Greinacher A, Nieuwenhuis HK, White JG. Sebastian platelet syndrome: A new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut. 1990;61:282–288
  8. Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome—A variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood. 1985;65:397–406
  9. Epstein CJ, Sahud MA, Piel CF, et al. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med. 1972;52:299–310
  10. Cawley JC, Hayhoe FG. The inclusions of the May-Hegglin anomaly and Dohle bodies of infection: An ultrastructural comparison. Br J Haematol. 1972;22:491–496
  11. Balduini CL, Iolascon A, Savoia A. Inherited thrombocytopenias: From genes to therapy. Haematologica. 2002;87:860–880
  12. Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82:203–215
  13. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet. 2001;69:1033–1045
  14. Kunishima S, Matsushita T, Kojima T, et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet. 2001;46:722–729
  15. No authors listed A.C. Alport. Br Med J. 1959;1:1191–1192
  16. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184
  17. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185–1192
  18. Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75:736–745
  19. Freedman BI, Kopp JB, Winkler CA, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN Study. Am J Nephrol. 2009;29:626–632
  20. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol. 2005;130:620–627
  21. Pecci A, Panza E, Pujol-Moix N, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat. 2008;29:409–417
  22. Kunishima S, Matsushita T, Yoshihara T, et al. First description of somatic mosaicism in MYH9 disorders. Br J Haematol. 2005;128:360–365
  23. Kunishima S, Takaki K, Ito Y, Saito H. Germinal mosaicism in MYH9 disorders: A family with two affected siblings of normal parents. Br J Haematol. 2009;145:260–262
  24. Simons M, Wang M, McBride OW, et al. Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes. Circ Res. 1991;69:530–539
  25. Berg JS, Powell BC, Cheney RE. A millennial myosin census. Mol Biol Cell. 2001;12:780–794
  26. Sellers JR. Myosins: A diverse superfamily. Biochim Biophys Acta. 2000;1496:3–22
  27. Maupin P, Phillips CL, Adelstein RS, Pollard TD. Differential localization of myosin-II isozymes in human cultured cells and blood cells. J Cell Sci. 1994;107:3077–3090
  28. Marigo V, Nigro A, Pecci A, et al. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics. 2004;83:1125–1133
  29. Chen Z, Naveiras O, Balduini A, et al. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood. 2007;110:171–179
  30. Davis JW, Wilson SJ. Platelet survival in the May-Hegglin anomaly. Br J Haematol. 1966;12:61–65
  31. Greinacher A, Mueller-Eckhardt C. Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes. Blut. 1990;60:53–60
  32. Kunishima S, Hamaguchi M, Saito H. Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders. Blood. 2008;111:3015–3023
  33. Kunishima S, Kojima T, Matsushita T, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood. 2001;97:1147–1149
  34. Pecci A, Noris P, Invernizzi R, et al. Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders. Br J Haematol. 2002;117:164–167
  35. Hartwig JH, DeSisto M. The cytoskeleton of the resting human blood platelet: Structure of the membrane skeleton and its attachment to actin filaments. J Cell Biol. 1991;112:407–425
  36. Wei Q, Adelstein RS. Conditional expression of a truncated fragment of nonmuscle myosin II-A alters cell shape but not cytokinesis in HeLa cells. Mol Biol Cell. 2000;11:3617–3627
  37. Milton JG, Hutton RA, Tuddenham EG, Frojmovic MM. Platelet size and shape in hereditary giant platelet syndromes on blood smear and in suspension: Evidence for two types of abnormalities. J Lab Clin Med. 1985;106:326–335
  38. Di Pumpo M, Noris P, Pecci A, et al. Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica. 2002;87:943–947
  39. Kunishima S, Matsushita T, Kojima T, et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: Association of subcellular localization with MYH9 mutations. Lab Invest. 2003;83:115–122
  40. Mills EL, Quie PG. Congenital disorders of the function of polymorphonuclear neutrophils. Rev Infect Dis. 1980;2:505–517
  41. Arrondel C, Vodovar N, Knebelmann B, et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol. 2002;13:65–74
  42. Ghiggeri GM, Caridi G, Magrini U, et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis. 2003;41:95–104
  43. Drenckhahn D, Franke RP. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest. 1988;59:673–682
  44. Kobor J, Turi S, Erdos A, Bodrogi T, Virag I. [Macrothrombopenia, nephritis and hearing loss—A new case of Epstein syndrome]. Orv Hetil. 1991;132:1875–1877
  45. Iyori H, Tokushige A, Ishitoya N, et al. [A case report of Epstein syndrome]. Nippon Jinzo Gakkai Shi. 1995;37:62–68
  46. Moxey-Mims MM, Young G, Silverman A, Selby DM, White JG, Kher KK. End-stage renal disease in two pediatric patients with Fechtner syndrome. Pediatr Nephrol. 1999;13:782–786
  47. Hamilton RW, Shaikh BS, Ottie JN, Storch AE, Saleem A, White JG. Platelet function, ultrastructure, and survival in the May-Hegglin anomaly. Am J Clin Pathol. 1980;74:663–668
  48. Jenis EH, Takeuchi A, Dillon DE, Ruymann FB, Rivkin S. The May-Hegglin anomaly: Ultrastructure of the granulocytic inclusion. Am J Clin Pathol. 1971;55:187–196
  49. Raveh D, Krausz Y, Eldor A. Successful splenectomy in May-Hegglin anomaly: Report of a case with platelet kinetic studies. Acta Haematol. 1989;82:43–45
  50. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet. 2000;67:1121–1128
  51. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica. 1999;84:891–896
  52. Pecci A, Granata A, Fiore CE, Balduini CL. Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant. 2008;23:2690–2692
  53. Alving BM, Tarassoff PG, Moore J, Leissenger CA, Fernandez-Bueno C. Successful renal transplantation for Epstein syndrome. Am J Hematol. 1986;21:111–113
  54. Urato AC, Repke JT. May-Hegglin anomaly: A case of vaginal delivery when both mother and fetus are affected. Am J Obstet Gynecol. 1998;179:260–261

 Originally published online as doi: 10.1053/j.ajkd.2009.06.023 on September 3, 2009.

PII: S0272-6386(09)00941-X

doi: 10.1053/j.ajkd.2009.06.023

American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 732-740 , October 2009

Article Tools

* Image Usage & Resolution